Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Interest Coverage : 5.71 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Amphastar Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Amphastar Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $54.0 Mil. Amphastar Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-9.5 Mil. Amphastar Pharmaceuticals's interest coverage for the quarter that ended in Dec. 2023 was 5.71. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Amphastar Pharmaceuticals's Interest Coverage or its related term are showing as below:

AMPH' s Interest Coverage Range Over the Past 10 Years
Min: 7.25 Med: 29.29 Max: 78.97
Current: 7.25

AMPH's Interest Coverage is ranked worse than
60.78% of 691 companies
in the Drug Manufacturers industry
Industry Median: 12.08 vs AMPH: 7.25

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amphastar Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Amphastar Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Amphastar Pharmaceuticals Interest Coverage Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

Get a 7-Day Free Trial

29.29

78.97

58.23

7.25

Amphastar Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage	Get a 7-Day Free Trial															71.65	84.00	10.24	5.30	5.71

Competitive Comparison of Amphastar Pharmaceuticals's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amphastar Pharmaceuticals's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Interest Coverage falls into.

Amphastar Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amphastar Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Amphastar Pharmaceuticals's Interest Expense was $-27.2 Mil. Its Operating Income was $197.0 Mil. And its Long-Term Debt & Capital Lease Obligation was $619.3 Mil.

Interest Coverage	=	-1	*	Operating Income (A: Dec. 2023 )	/	Interest Expense (A: Dec. 2023 )
	=	-1	*	196.987	/	-27.158
	=	7.25

Amphastar Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Amphastar Pharmaceuticals's Interest Expense was $-9.5 Mil. Its Operating Income was $54.0 Mil. And its Long-Term Debt & Capital Lease Obligation was $619.3 Mil.

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	53.98	/	-9.456
	=	5.71

The higher the ratio, the stronger the company's Financial Strength is.

Amphastar Pharmaceuticals (NAS:AMPH) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Amphastar Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

29A:Germany 29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

http://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Executives

Mary Z. Luo	director, 10 percent owner, officer: COO and Chief Scientist	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou	officer: EVP, Production	C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins	director
William J Peters	officer: CFO, SVP & Treasurer	C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi	officer: SVP Corp Admin Center	C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff	director
Gayle Deflin	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst	officer: EVP, QA & Regulatory Affairs	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee	director	13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang	director, 10 percent owner, officer: CEO & Chief Scientific Officer	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris	director	C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell	director, officer: President	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc.	10 percent owner	13760 MAGNOLIA AVENUE, CHINO CA 91710